Vicki L. Sato, Ph.D.
Professor
Harvard Business School

Vicki L. Sato, Ph.D, is Professor of Management Practice at Harvard Business School, and also Professor of the Practice in the Department of Molecular and Cell Biology, Harvard University. Dr. Sato retired recently from Vertex Pharmaceuticals, where she served as President since 2000. Before joining Vertex, Dr. Sato was Vice President of Research at Biogen, Inc. Currently, Dr. Sato is a member of the Board of Directors of Bristol Myers Squibb Company, PerkinElmer Corporation, Infinity Pharmaceuticals, and Alnylam Pharmaceuticals. She also serves as a business advisor to Atlas Ventures. Dr. Sato received her AB from Radcliffe College, and her AM and PHD degrees from Harvard University.

Dr. Scott Cannizzaro
Senior Director, Stem Cell Internal Venture
Johnson & Johnson

Dr. Scott Cannizzaro is a Senior Director with the Stem Cell Internal Venture at Johnson & Johnson where he leads operations, development and strategic planning. Dr. Cannizzaro is a founding member of the J&J Internal Ventures group whose focus is on the acceleration of high risk – high reward innovative technologies. Prior to joining Johnson & Johnson, he held both senior research and business development positions at several venture-stage biotechnology companies and served as a consultant with Arthur D. Little where he managed client engagements in pharmaceuticals, medical devices and biotechnology. He has worked directly on a broad range of technologies from drug discovery to contact lenses . Dr. Cannizzaro graduated from Duke University with a PhD in organic chemistry and was awarded a NIH fellowship to study biomedical engineering at the Massachusetts Institute of Technology with Robert Langer. He is also a graduate of the Wharton School of Business where he majored in Healthcare Management.

Sohang Chatterjee
Chairman, Chief Executive
Inbioprio Solutions

Sohang Chatterjee is a founder member of Inbiopro Solutions, an Indian Biotech Company specializing in process development for biologics. Sohang holds a master's degree in molecular biology from the National Center for Biological Sciences (Tata Institute of Fundamental Research) in India as well as over 5 years of research experience at Cornell University, Ithaca. Upon returning to India in 2000, he served as the head of Process Development at Millipore India for nearly seven years followed by a year with Avesthagen as their Head of Downstream Process Development. With extensive experience in process development working on development projects for biotech players in India and their global technology partners, Sohang and his team focus on combining biology and engineering in taking biologics to large scale manufacturing.

Judith K. Gwathmey
Founder and CEO
Gwathmey, Inc.

Judith K. Gwathmey is the founder and CEO of Gwathmey, Inc. She is Professor of Medicine and Physiology at Boston University Medical School and Tufts School of Veterinary Medicine. Dr. Gwathmey was formerly Associate Professor of Medicine at Harvard Medical School. Dr. Gwathmey has a B.A. and V.M.D. (veterinary medical degree with honors) from the University of Pennsylvania, and a Ph.D. from The Ohio State University in veterinary physiology and pharmacology. She is a fellow of the American College of Cardiology (F.A.C.C.) and the American Heart Association (F.A.H.A.). Dr. Gwathmey is the 2001 Presidential Mentoring Award recipient.

Jan Skvarska
Partner
Bain & Company

Jan Skvarska is a partner in the Bain Boston office, with experience primarily in the health care industry, helping biotech, pharma, and life sciences clients on a variety of issues. Projects included organizational redesign, post-merger integration, growth and portfolio strategy, business plan development, among others. Prior to joining Bain, Jan worked with Pricewaterhouse Corporate Finance, London. He advised clients on project finance, privatization, M&A and regulatory issues. Jan earned an MBA from Harvard Business School in 1999. He holds BS and PhD degrees from the University of Economics in Slovakia. He is also a Certified Accountant in Austria

Barbara McNeil, MD, PhD
Professor, Harvard Medical School and Brigham and Women's Hospital
Founding Head of the Department of Health Care Policy, Harvard Medical School

Barbara J. McNeil, MD, PhD, is the Ridley Watts Professor and founding head of the Department of Health Care Policy at Harvard Medical School. She is also a professor of radiology at Harvard Medical School and at Brigham and Women's Hospital. Dr. McNeil's research activities have focused on several areas, most notably technology assessment and quality of care. Her most recent work includes two large studies supported by the Department of Veterans Affairs. The first focused on a comparison of quality of care for veterans with cardiac disease with the care provided to Medicare beneficiaries seen in private settings. Its report led to the introduction of many changes in the care of veterans with cardiac disease.

Dr. Robert Crone
Chief Executive Officer
Harvard Medical International

Dr. Crone joined the Harvard Medical School faculty as Dean for International programs, and Clinical Professor of Anaesthesia in 1994, and is currently on the adjunct clinical staff at Children's Hospital. Dr. Crone provides the overall leadership and strategic direction of Harvard Medical International and its programs. He interfaces with the Dean of Harvard Medical School, HMI's Board of Directors, and Harvard University's Central Administration on policy decisions, including decisions to engage in new projects. Dr. Crone has extensive knowledge of medical education and health care provision around the world, in both public and private sectors.

Webster Golinkin
Chief Executive Officer
RediClinic

Mr. Golinkin serves as CEO of RediClinic, which provides health screenings and flu shots at retail outlets and employer worksites nationwide and operates RediClinic 'convenient care' centers in four states. Mr. Golinkin was named President of the Convenient Care Association in October 2007. For the past 23 years, Mr. Golinkin has served as chairman, vice chairman, president, and/or chief executive officer of five companies, including three in the health field. In 1988, he co-founded and served as President and CEO of American Medical Communications, Inc., which became one of the nation's largest producers and distributors of health-related television and video programming. In 1993, he co-founded and served as Chairman and CEO of America's Health Network, Inc., which became the nation's largest health-related cable television network. Mr. Golinkin earned a B.A. from Harvard University and is a member of World Presidents' Organization.

James Hummer
Founder, President and CEO
Whole Health Management

Jim Hummer heads Whole Health Management, an innovative provider of direct contract, on-site employee health services to leading self-insured companies. It provides integrated health services including occupational, preventive, urgent and primary health care services, health risk and disease management, physical therapy, fitness programs and behavioral health services. Clients include Sprint, Qualcomm, Florida Power & Light, Continental Airlines and Harrah's Entertainment. Before Whole Health, he co-founded and was president of the Ivy Medical Group, an ambulatory health care company. Previously, he was Director of Planning and Human Resources at Martin Marietta Corporation's Chemical Group. Earlier, he was with Deloitte, Haskins & Sells. He holds a BA in accounting from the University of Notre Dame and his MBA from Harvard.

Jon Kingsdale, Ph.D.
Executive Director
Commonwealth Health Insurance Connector Authority

Jon Kingsdale is the Executive Director of the Commonwealth Health Insurance Connector Authority, an independent authority established to promote coverage of the uninsured. As a senior executive at the Tufts Health Plans for almost twenty years, he was responsible for strategic planning, product development, public affairs and government relations. His work experience also includes executive roles in strategic planning and reimbursement at Blue Cross Blue Shield of Massachusetts, and research on hospital finances at the Harvard School of Public Health. He received a doctorate in economic history from the University of Michigan and a B.A. from the University of Pennsylvania.

Dr. Peter L. Slavin
President
Massachusetts General Hospital

Peter L. Slavin, M.D. is the President of Massachusetts General Hospital (MGH) and Professor of Health Care Policy at Harvard Medical School. MGH operates 900 inpatient beds, has an annual operating budget of $1.9 billion, and has the largest hospital research program in the country. Previously, he served as the Senior Vice President and Chief Medical Officer at MGH and as the president of the Barnes-Jewish Hospital in St. Louis, Missouri. Dr. Slavin also served as the Chairman and CEO of the Massachusetts General Physicians Organization. Dr. Slavin is a graduate of Harvard College, Harvard Medical School, and Harvard Business School.

Moderator
Don Munoz
Managing Director, Head of Medical Technology Investment Banking
Leerink Swann

Don Munoz leads Leerink Swann's medical technology investment banking practice. Prior to joining Leerink Swann in 2005, Don spent ten years at Deutsche Bank, BT Alex. Brown and Alex. Brown & Sons in that firm's health care investment banking group. During his career, he has completed over 80 public and private equity offerings, high yield, investment-grade and bank debt transactions, and buyside and sellside mergers and acquisitions across all sectors of health care. Don received an MBA from Columbia Business School, where he was elected to Beta Gamma Sigma, and a BA from Dartmouth College.

Noubar Afeyan, PhD
Managing Partner and CEO
Flagship Ventures

Noubar is a technologist, entrepreneur and venture capitalist. He has founded and helped build 15 successful life science and technology startups during the past two decades. In 1999, Noubar co-founded Flagship Ventures, an early stage venture capital and entrepreneurship firm. In addition, he is a Senior Lecturer at MIT in both the Sloan School of Management and the Biological Engineering Department, a member of the Boston University Board of Overseers and a member of several advisory boards. Noubar has authored numerous scientific publications as well as patents, and earned his Ph.D. in Biochemical Engineering from MIT in 1987.

Richard J. Cohen, M.D., Ph.D.
Co-Director of the Biomedical Enterprise Program
Harvard University - Massachusetts Institute of Technology

Richard J. Cohen, M.D., Ph.D. is Whitaker Professor in Biomedical Engineering in the Harvard University - Massachusetts Institute of Technology Division of Health Sciences and Technology. He is currently Co-Director of the Biomedical Enterprise Program. He previously directed the Center for Biomedical Engineering at MIT and was the Cardiovascular Team Lead for the National Space Biomedical Research Institute. His research interests involve the application of physics and engineering to the development of new diagnostic and therapeutic technologies particularly in the cardiovascular area. He founded Cambridge Heart, Inc. which markets a technology developed in his laboratory at MIT for identifying patients at risk for sudden cardiac death.

E. Hunterson Henrie, II, MA
Managing Director
Ferghana Partners

Hunt Henrie joined Ferghana Partners in 2002 with responsibility for the Equity Financing activities of the firm's clients as well as the creation and execution of M&A and Corporate Partnering deals in the Diagnostics/Medical Equipment fields. Hunt is an experienced financial, strategic and biomedical executive with over 15 years of broad-based global financial, investment banking, private equity and corporate operating experience. Hunt received his BA, cum laude, in International Relations from Boston University, his MA in International Economics from Johns Hopkins School of Advanced International Studies (SAIS), and an Executive Certificate in Financial Management from the Graduate School of Business of Stanford University.

Georg Nebgen, Ph.D.
Co-Founder and Managing General Partner
NGN Capital

Dr. Georg Nebgen is a Co-Founder and Managing General Partner of NGN Capital. He joined from MPM Capital where he had previously been Principal at MPM Capital in Boston and Managing Director of MPM Capital GmbH. Prior to this, Dr. Nebgen was with Schering-Plough Corporation and F. Hoffmann-La Roche in the U.S. and Switzerland. He obtained his doctorate in Pharmaceutical Technology Sciences from the University of Bonn, Germany and his executive MBA from the University of St. Gallen, Switzerland. Dr. Nebgen currently serves on the Board of Directors of Javelin Pharmaceuticals, Inc. (AMEX: JAV), Santhera Pharmaceuticals AG (SWX: SANN), Artisan Pharma, Inc., KIKA Medical Inc. and Tigris Pharmaceuticals, Inc.

Stephen N. Oesterle, M.D.
Senior Vice President for Medicine and Technology
Medtronic

Stephen N. Oesterle, M.D., joined Medtronic in 2002, after serving as Associate Professor of Medicine at the Harvard University Medical School and Director of Invasive Cardiology Services at Massachusetts General Hospital. In his current position, Oesterle provides executive leadership for scientific research, formation of technological strategies and continued development of strong cooperative relationships with the world's medical communities. A teacher and innovator in the field of cardiac catheterization, Oesterle developed and directed interventional cardiology programs at Good Samaritan Hospital, Los Angeles from 1986 to 1991; at Georgetown University in 1991 and 1992 and at Stanford University from 1992-98.

John T. Santini, Jr., PhD
President & CEO
MicroCHIPS, Inc.

John Santini is an entrepreneur with over a decade of experience in drug delivery and biosensing. Under his leadership, MicroCHIPS has attracted top tier venture capital and corporate investors and demonstrated the first long-term implantable drug delivery microchip. He is a recognized expert in the application of microtechnology in healthcare and has over 60 issued/pending patents. Dr. Santini was honored as one of the Top 100 Young Innovators in the world by Technology Review Magazine. He obtained his PhD in chemical engineering from MIT with Professors Robert Langer and Michael Cima as a National Science Foundation Fellow.

Jacques Mulder
Partner, New York Office
Deloitte Consulting

Jacques has over 15 years of Life Sciences experience and he is guiding some of Deloitte Consulting's most important engagements for leading global pharmaceutical companies. He has deep experience across the entire pharmaceutical value chain, particularly in drug commercialization (U.S. and global) and post-launch clinical research. Prior to joining Deloitte, Jacques served as Senior VP of Integrated Strategic Solutions for a large pharmaceutical research consulting firm. He has held responsibility for several consulting functions, including corporate strategy, R&D portfolio and marketing strategy, clinical development, data management, bio statistics, and site monitoring.

Nancy T. Chang, Ph.D.
Managing Director
OrbiMed Advisors

Dr. Chang is Managing Director at OrbiMed Advisors. Previously, Dr. Chang was the Co-Founder, CEO and Chairman of Tanox, Inc which she lead the company to the second-largest IPO ever for a biopharmaceutical company at that time, and in 2007 sold to Genentech for $919 million. Dr. Chang serves on the BOD of the Federal Reserve Bank in Houston, Charles River Laboratories, and she is also a member of the Board of Visitors at M. D. Anderson Cancer Center. Before launching Tanox, Dr. Chang served as Director of Research at Centocor, and received her Ph.D. in Biological Chemistry from Harvard University.

Jesper Hoiland
Senior Vice President
Novo Nordisk

Jesper Høiland is Senior Vice President with Novo Nordisk, one of the world's leading diabetes care companies. Jesper is responsible for Region International Operations - 150 countries including the BRIC countries - and 3,500 employees and has worked for the company for more than 20 years. He obtained his MSc from Copenhagen Business School. He has spent most of his professional career within pharma in Canada, Belgium, France, Australia and Switzerland. He is married and has two children.

Shabnam Kazmi
Vice President, U.S. Business Development
sanofi-aventis

Shabnam Kazmi is currently Vice President, Business Development for the U.S. affiliate of sanofi-aventis, the third largest pharmaceutical company in the world with headquarters in Paris, France. Shabnam joined sanofi-aventis in 2003 as Director, Oncology Marketing and led the marketing of Eloxatin, the most successful chemotherapeutic launched to date. She was promoted to Senior Director in 2004 and again to Associate Vice President in 2005, assuming responsibility for oncology new drug commercialization and key customer interfaces. In her current role, Shabnam heads up business development, licensing and alliance management for sanofi-aventis U.S. across therapeutic areas, focusing on the company's core strengths in cardiovascular, oncology, central nervous system and respiratory diseases. Shabnam has a Bachelor's degree in Biochemistry and Economics from Smith College and an MBA from Harvard Business School.

Anil Soni
Executive Vice President for Access Programs
Clinton Foundation HIV/AIDS Initiative

Anil Soni is Executive Vice President for Access Programs at the Clinton Foundation HIV/AIDS Initiative, where he leads global activities to negotiate pricing agreements with suppliers of HIV/AIDS medicines and diagnostics and to assist more than 60 countries access associated products and prices. From 2004 to 2005, Anil was the Executive Director of Friends of the Global Fight, a nonprofit that advocates in the United State for increased public leadership and private engagement to support the Global Fund to Fight AIDS, Tuberculosis and Malaria. Previously, Anil served as the Advisor to the Executive Director of the Global Fund in Geneva, where he provided senior policy counsel to guide the organization's development and operations in its first two years. Anil was also a consultant at McKinsey and Company, where he served such clients as the Bill & Melinda Gates Foundation and the Botswana Ministry of Health. He also worked for the Northwestern Memorial Hospital, in the White House Office of National AIDS Policy, and with nongovernmental organizations in Ghana and the Middle East. Anil graduated magna cum laude from Harvard College in 1998.

Moderator:
Regina E. Herzlinger
Professor
Harvard Business School

Regina E. Herzlinger is the Nancy R. McPherson Professor of Business Administration Chair at the Harvard Business School. She was the first woman to be tenured and chaired at HBS and the first to serve on a number of corporate boards. She is widely recognized for her innovative research in health care, including her early predictions of the unraveling of managed care and the rise of consumer-driven health care. Her newest book, Who Killed Health Care?, is on the CEO Best Seller List. Modern Healthcare readers selected her as among the "100 Most Powerful People in Healthcare" each year since 2003. She has served on the Scientific Advisory Group to the U.S. Secretary of the Air Force and as a board member of several Fortune 500 firms.

Stephen Bollinger
President and COO
Pervasis Therapeutics

Stephen Bollinger assumed the role of President and COO at Pervasis Therapeutics in June 2005. Prior to Pervasis, he was a founder and COO of Angiolink Corporation, a medical device company which was sold to Medtronic Corporation in 2004. From 1997 to 1999 he served as VP of R&D and Operations for Byron Medical. He sold the company to Mentor Corporation in 1999. From 1991 to 1997, he held several sales and marketing positions at various medical device companies. Mr. Bollinger served as an artillery officer in the US Army for four years. He received a BS from US Military Academy and an M.B.A. from Oklahoma City University.

Dr. Jonathan Fleming
Managing General Partner
Oxford Bioscience Partners

Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners. Dr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe, and Israel. He co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare companies in Israel. He is a co-founder and Chairman of the Board of Memory Pharmaceuticals. He is also Chairman of the Board of BioProcessors Corporation and is a director of several private companies including Leerink Swann, a Boston healthcare-focused investment bank. Dr. Fleming is a Senior Lecturer at the MIT Sloan School of Business.

Todd Foley
Venture Partner
MPM Capital

Todd Foley is a Venture Partner at MPM Capital and a General Partner managing the MPM-Novartis BioVentures IV Strategic Fund. Prior to joining MPM in 1999, Todd Foley worked in Business Development at Genentech and management consulting with Arthur D. Little. He holds an M.B.A. from Harvard Business School where he was co-president of the Healthcare & Biotechnology Club. At MPM, he has been actively involved in over 15 investments including serving as COO for Centagenetix and VP of Business Development for AVEO Pharmaceuticals. He is a member of the Board of Directors of Alinea Pharmaceuticals, NeuroMed, and Primera Biosystems; and a past board member of several other portfolio companies.

Dr. John Freund
Founder
Skyline Ventures

Dr. Freund has been involved in founding, financing, and managing healthcare companies since 1982. He began his career at Morgan Stanley in New York, where he was the original healthcare partner at Morgan Stanley Ventures. In 1995, he founded Intuitive Surgical, Inc, which now produces over $400 Million in annual revenue. He founded Skyline Ventures, an international healthcare venture capital firm, in 1997. He has experience with most of the major sectors of the healthcare investment market including medical devices, information technology, biotechnology, and diagnostics. He received a B.A. from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he won the Loeb Fellowship in Finance.

Kevin Starr
Partner
Third Rock Ventures

Kevin has more than 20 years of experience in management of finance, technology, and operations in biotech. As COO/CFO of Millennium, Kevin led the business teams responsible for raising several billion dollars through partnerships and equity offerings. Kevin held leadership positions at Biogen, and he serves on the board of directors for several leading biotech companies.

Dr. Albert Waxman
Senior Managing Member
Psilos

Dr. Waxman founded Psilos, an international venture capital firm, after a lengthy career as an entrepreneur in the healthcare field. He most recently served as Chairman and CEO of Merit Behavioral Care and its predecessor company, American Biodyne. During this period, he brought American Biodyne public and grew the company's revenues to over $800 million. Prior to that, he founded and served as CEO of Diasonics, Inc., one of the first American ultrasound and MRI companies. He is chairman and/or director of several Psilos portfolio companies. He serves as a Director of the New York City Investment Fund, holds a BS from the City College of New York, and a PHD from Princeton.

Andrew P. Vaz
Principal
Deloitte Consulting, LLP

Andrew Vaz is the National Director of Deloitte's Life Sciences practice responsible for all services and solutions. Andrew is also responsible for the development of all intellectual capital and methodologies to support the transformation of Life Sciences companies. He has over 20 years of experience in the healthcare industry across the Health Plan, Provider, Government Health, and Life Sciences sectors. Prior roles include Managing Director of the Canadian and Northeast Healthcare and Life Sciences practices at Ernst & Young. Andrew received his Masters of Health Sciences, Health Services Administration at University of Toronto, Toronto, Canada, his Bachelor of Science Honours at University of Toronto, Toronto, Canada and participated in the Executive Program at Northwestern University.

Drew Fromkin
President and Chief Executive Officer, Director
Clinical Data

Mr. Fromkin joined Clinical Data on October 12, 2005, as the Executive Vice President and Chief Marketing Officer, and was elected President and Chief Executive Officer on May 12, 2006. He was most recently President and CEO of DoctorQuality, Inc., a leading provider of patient safety products and information services that was acquired by Quantros, Inc. Prior to that, Mr. Fromkin held several senior management roles at emerging healthcare companies, including executive appointments as President and Chief Executive Officer of Endo Surgical Devices, Inc., where his achievements included developing a line of innovative surgical devices, securing funding for the company, and guiding the company to its first FDA approval. Mr. Fromkin also was Vice President, Business Development and before that, Vice President, Sales for Merck-Medco Managed Care, LLC, a wholly owned subsidiary of Merck & Co., Inc.

Jeremy P. Goldberg
Managing Director, Corporate Development
Endo Pharmaceuticals

Jeremy P. Goldberg joined Endo in 2003 as Managing Director, Corporate Development. In this position, Mr. Goldberg is responsible for Endo's overall corporate development activities including structuring, negotiating and closing transactions such as the acquisition of companies, technology, products and product lines. Mr. Goldberg has 20+ years of experience, much of which was focused on investing and business development activities in the pharmaceutical and healthcare industries. Most recently, he was a founding partner with ProQuest Investments, the first cancer-focused venture capital fund. In the mid-1990s, he was the founding CEO of Versicor, Inc.,. He also held marketing and business development assignments at Becton Dickinson and SmithKline Beckman. Mr. Goldberg is a graduate of Harvard College and Harvard Business School ('88). He serves on visiting committees at the Dana Farber Cancer Institute and the UCSF Cancer Center.

Steve Mickel
Director of Global Strategic Marketing, Oncology
Abbott Laboratories

Steve is the Director of Global Strategic Marketing for Oncology in Abbott's Pharmaceutical Products Group. Steve is an HBS MBA (Class of '84) and also holds a BS degree in Chemical Engineering from MIT. Steve has focused exclusively on healthcare since graduating from HBS, serving in marketing and business development management positions at Abbott, Baxter and Becton Dickinson, and in financing and operating roles with a number of biotech start-ups.

Amir Nashat
General Partner
Polaris Ventures

Amir Nashat is a general partner at Polaris Ventures. Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir's doctoral research focused on information flow through neurons, neural implants, and neural tissue engineering. During his time at M.I.T., Amir completed an internship in the London office of Goldman, Sachs & Company, where he worked on interest rate derivative products. Prior to obtaining his Ph.D. at MIT, Amir earned both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.